Table 8.
Class/mechanism of action | Medications | Higher risk of infection |
---|---|---|
Tumor necrosis factor (anti-TNF) antagonists | Etanercept Adalimumab Infliximab |
Tuberculosis Fungal, bacterial and viral infections |
T lymphocyte co-stimulation blocker (CTLA4-Ig) | Abatacept | Worsening of active infections by any pathogen |
B lymphocyte depletion (anti-CD20) | Rituximab | Reactivation of the Hepatitis B virus |
Interleukin 6 (IL-6) receptor blocker | Tocilizumab | Worsening of active infections by any pathogen |
Adapted from da Mota et al.17